Stock RDHL REDHILL BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Real-time Estimate Cboe BZX
Other stock markets
 12:06:45 2024-05-07 EDT 		5-day change 1st Jan Change
0.456 USD +0.86% Intraday chart for RedHill Biopharma Ltd. +5.50% -68.84%
05-06 Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib MT
05-06 RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences
Redhill Biopharma Closes $8 Million Registered Direct Offering of American Depositary Shares
RedHill Biopharma to Seek Acquisitions
Top Midday Decliners
Redhill Biopharma Launches $8 Million Offering of American Depositary Shares; Stock Falls
Sector Update: Health Care Stocks Retreat Late Afternoon
Sector Update: Health Care Stocks Mixed in Wednesday Afternoon Trading
Redhill Says Opaganib, RHB-107 Combinations With Remdesivir Show 'Robust Synergistic Effect' Against Ebola; Shares Rise
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
U.S.-LISTED SHARES OF REDHILL BIOPHARMA RISE 2.4% ON ADDITIONAL…
Redhill Biopharma Says it Received $4.8 Million in Additional Funds for Study of Early COVID-19 Treatment
Top Premarket Decliners
Top Premarket Gainers
Top Premarket Gainers
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RDHL Stock
  4. News RedHill Biopharma Ltd.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW